These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30718563)

  • 1. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
    Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
    Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly.
    Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Chimelli L; Luque RM; Kasuki L; Gadelha MR
    J Cell Mol Med; 2018 Apr; 22(4):2110-2116. PubMed ID: 29377493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A; Mantovani G; Spada A
    Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
    Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
    Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
    Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
    Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
    Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
    PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
    Gatto F; Arvigo M; Ferone D
    J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
    Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
    Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization.
    Treppiedi D; Jobin ML; Peverelli E; Giardino E; Sungkaworn T; Zabel U; Arosio M; Spada A; Mantovani G; Calebiro D
    Endocrinology; 2018 Aug; 159(8):2953-2965. PubMed ID: 29931263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
    Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.